Discovering drugs for the treatment of Ebola virus
Abstract
Drug development for Ebola virus (EBOV) has been in progress for several decades, primarily fueled by concerns about the potential use of the Category A agent as a potential bioweapon. However, the unprecedented magnitude and scale of the 2014-2016 outbreak in West Africa, combined with the potential spread to other corners of the world, led to a renewed focus on medical countermeasures for Ebola virus disease (EVD).
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 04, 2017
- Accession Number
- AD1038259
Entities
People
- Allen J. Duplantier
- Sandra L Bixler
- Sina Bavari
Organizations
- United States Army Medical Research Institute of Infectious Diseases